X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Aurobindo Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs AUROBINDO PHARMA - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA AUROBINDO PHARMA GLENMARK PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 12.1 14.2 85.1% View Chart
P/BV x 3.2 3.6 87.6% View Chart
Dividend Yield % 0.4 0.4 88.3%  

Financials

 GLENMARK PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-17
AUROBINDO PHARMA
Mar-17
GLENMARK PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs993895 110.9%   
Low Rs729622 117.3%   
Sales per share (Unadj.) Rs325.5254.6 127.9%  
Earnings per share (Unadj.) Rs39.339.3 100.0%  
Cash flow per share (Unadj.) Rs48.746.6 104.5%  
Dividends per share (Unadj.) Rs2.002.50 80.0%  
Dividend yield (eoy) %0.20.3 70.5%  
Book value per share (Unadj.) Rs159.2160.0 99.5%  
Shares outstanding (eoy) m282.17585.88 48.2%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.63.0 88.8%   
Avg P/E ratio x21.919.3 113.5%  
P/CF ratio (eoy) x17.716.3 108.7%  
Price / Book Value ratio x5.44.7 114.1%  
Dividend payout %5.16.4 80.0%   
Avg Mkt Cap Rs m242,991444,390 54.7%   
No. of employees `00013.014.0 92.7%   
Total wages/salary Rs m16,40817,678 92.8%   
Avg. sales/employee Rs Th7,083.910,667.8 66.4%   
Avg. wages/employee Rs Th1,265.41,264.3 100.1%   
Avg. net profit/employee Rs Th855.11,645.8 52.0%   
INCOME DATA
Net Sales Rs m91,857149,157 61.6%  
Other income Rs m3741,159 32.2%   
Total revenues Rs m92,230150,316 61.4%   
Gross profit Rs m20,36734,343 59.3%  
Depreciation Rs m2,6444,276 61.8%   
Interest Rs m2,373667 355.7%   
Profit before tax Rs m15,72430,558 51.5%   
Minority Interest Rs m050 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8100-   
Tax Rs m3,8277,597 50.4%   
Profit after tax Rs m11,08823,012 48.2%  
Gross profit margin %22.223.0 96.3%  
Effective tax rate %24.324.9 97.9%   
Net profit margin %12.115.4 78.2%  
BALANCE SHEET DATA
Current assets Rs m68,74692,062 74.7%   
Current liabilities Rs m27,02766,223 40.8%   
Net working cap to sales %45.417.3 262.2%  
Current ratio x2.51.4 183.0%  
Inventory Days Days85106 80.2%  
Debtors Days Days9668 141.2%  
Net fixed assets Rs m24,13262,919 38.4%   
Share capital Rs m282586 48.2%   
"Free" reserves Rs m44,64393,133 47.9%   
Net worth Rs m44,92593,719 47.9%   
Long term debt Rs m45,3631,814 2,500.7%   
Total assets Rs m117,639162,494 72.4%  
Interest coverage x7.646.8 16.3%   
Debt to equity ratio x1.00 5,216.8%  
Sales to assets ratio x0.80.9 85.1%   
Return on assets %11.414.6 78.5%  
Return on equity %24.724.6 100.5%  
Return on capital %19.132.7 58.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,15275,838 74.0%   
Fx outflow Rs m8,08430,224 26.7%   
Net fx Rs m48,06845,613 105.4%   
CASH FLOW
From Operations Rs m6,57432,786 20.1%  
From Investments Rs m-7,124-17,870 39.9%  
From Financial Activity Rs m5,432-19,153 -28.4%  
Net Cashflow Rs m1,992-4,239 -47.0%  

Share Holding

Indian Promoters % 48.3 54.1 89.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 8.0 86.8%  
FIIs % 34.4 27.7 124.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 10.2 102.9%  
Shareholders   56,727 69,601 81.5%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   SUVEN LIFE  SHASUN PHARMA  PFIZER  FDC LTD.  ORCHID PHARMA LTD  

Compare GLENMARK PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade Marginally Lower; Energy Stocks Witness Losses(11:30 am)

Share markets in India are presently trading marginally lower. Sectoral indices are trading on a mixed note with stocks in the energy sector and auto sector witnessing maximum selling pressure.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Feb 22, 2018 12:55 PM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS